Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Allarity Therapeutics, Inc.

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics to Present at Biomarkers 2024
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics to Present at Biomarkers Europe 2023
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.